| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
JENBURKT PHARMACEUTICALS LTD. (BSE: 524731)
524731 Technical Analysis
5
| As on 24th Dec 2024 524731 SHARE Price closed @ 1213.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 745.91 & Strong Buy for SHORT-TERM with Stoploss of 824.82 we also expect STOCK to react on Following IMPORTANT LEVELS. |
524731SHARE Price
| Open | 1218.00 | Change | Price | % |
| High | 1218.00 | 1 Day | -4.45 | -0.37 |
| Low | 1190.10 | 1 Week | 336.00 | 38.29 |
| Close | 1213.55 | 1 Month | 336.00 | 38.29 |
| Volume | 323 | 1 Year | 533.45 | 78.44 |
| 52 Week High 1218.00 | 52 Week Low 660.05 | ||||
BSE INDIA Most Active Stocks
| 532822 | 7.47 | -0.13% |
| 532411 | 0.41 | 0.00% |
| 517001 | 0.09 | 12.50% |
| 511700 | 1.01 | -0.98% |
| 512149 | 0.88 | 0.00% |
| 511389 | 7.25 | -2.42% |
| 534690 | 7.65 | 4.79% |
| 532775 | 2.04 | -0.97% |
| 531328 | 1.05 | 0.96% |
| 532648 | 19.80 | -0.60% |
BSE INDIA Top Gainers Stocks
BSE INDIA Top Losers Stocks
| 524731 Daily Charts |
524731 Intraday Charts |
Whats New @ Bazaartrend |
524731 Free Analysis |
|
|
524731 Important Levels Intraday
| RESISTANCE | 1267.31 |
| RESISTANCE | 1250.07 |
| RESISTANCE | 1239.41 |
| RESISTANCE | 1228.76 |
| SUPPORT | 1198.34 |
| SUPPORT | 1187.69 |
| SUPPORT | 1177.03 |
| SUPPORT | 1159.79 |
524731 Target August 2025
| 4th UP Target | 0 |
| 3rd UP Target | 0 |
| 2nd UP Target | 0 |
| 1st UP Target | 0 |
| 1st DOWN Target | 0 |
| 2nd DOWN Target | 0 |
| 3rd DOWN Target | 0 |
| 4th DOWN Target | 0 |
524731 Weekly Target
| 4th UP Target | 0.00 |
| 3rd UP Target | 0.00 |
| 2nd UP Target | 0.00 |
| 1st UP Target | 0.00 |
| 1st DOWN Target | 0.00 |
| 2nd DOWN Target | 0.00 |
| 3rd DOWN Target | 0.00 |
| 4th DOWN Target | 0.00 |
524731 Target2025
| 4th UP Target | 1118.35 |
| 3rd UP Target | 977.82 |
| 2nd UP Target | 890.95 |
| 1st UP Target | 804.08 |
| 1st DOWN Target | 556.22 |
| 2nd DOWN Target | 469.35 |
| 3rd DOWN Target | 382.48 |
| 4th DOWN Target | 241.95 |
JENBURKT PHARMACEUTICALS LTD. ( BSE INDIA Symbol : 524731 )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
524731 Business Profile
Jenburkt Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical formulations primarily in India. It offers products in various therapeutic areas, such as pain management, neuropathic pain, anthelmintics, analgesics and antipyretics, anti-arthritic, anti-diabetic, anti-infective, anti-fungal, anti-malarial, anti-ulcerant/antacid, aphrodisiac, cough and cold, and muscle relaxants, as well as nutraceutical and consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government and semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries. The company was founded in 1985 and is based in Mumbai, India. Address: Nirmala Apartments, Mumbai, India, 400058
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service